196 related articles for article (PubMed ID: 33081582)
1. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Cakir B
J Oncol Pharm Pract; 2020 Dec; 26(8):2068-2069. PubMed ID: 33081582
[No Abstract] [Full Text] [Related]
2. Tyrosine kinase inhibitors and COVID-19.
Semih B; Tuğçe Nur Y; Mehmet Sinan D; Serdal K; Burhan T; Fevzi A
J Oncol Pharm Pract; 2020 Dec; 26(8):2072-2073. PubMed ID: 33081581
[No Abstract] [Full Text] [Related]
3. What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
Delgado N; Torres A
Curr Oncol Rep; 2022 May; 24(5):645-650. PubMed ID: 35218499
[TBL] [Abstract][Full Text] [Related]
4. Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience.
Nesr G; Saleem Z; Arami S
J Med Virol; 2022 Apr; 94(4):1274-1276. PubMed ID: 34914847
[No Abstract] [Full Text] [Related]
5. COVID-19 in chronic myeloid leukemia patients in Latin America.
Pagnano KB; Peralta EH; Navarro JR; David Salas LDR; Delgado N; Moiraghi B; Toreli ACM; Perobelli LM; Fechio L; Quixada ATS; Funke V; Bendit I; Seguro FS; Pilleux L; Bortolini J; Lourenço ALG; Sapelli J; Nucci FM; Pavlovsky C; Oliveira LDC; Moura MS; Palma LC; Gonçalves NN; Conchon M; Hokama POM; Almeida LL; Zulli R; de Souza CA; Boquimpani CM
Leuk Lymphoma; 2021 Dec; 62(13):3212-3218. PubMed ID: 34254886
[TBL] [Abstract][Full Text] [Related]
6. Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
Claudiani S; Apperley JF; Parker EL; Marchesin F; Katsanovskaja K; Palanicawandar R; Innes AJ; Tedder RS; McClure MO; Milojkovic D
Br J Haematol; 2022 Apr; 197(1):e1-e4. PubMed ID: 34923623
[No Abstract] [Full Text] [Related]
7. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Blurring of vision as the only symptom in an undiagnosed case of chronic myeloid leukemia in the COVID-19 era.
Gumaste P; Vairagyam R
Indian J Ophthalmol; 2021 Mar; 69(3):768-769. PubMed ID: 33595523
[No Abstract] [Full Text] [Related]
10. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.
Diab M; Schiffer CA
Leuk Res; 2019 Apr; 79():1-2. PubMed ID: 30776648
[No Abstract] [Full Text] [Related]
12. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Defuentes G; Bladé JS; Berets O
N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
[No Abstract] [Full Text] [Related]
14. Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review.
Asif M; Amir M; Hussain A; Achakzai NM; Natesan Pushparaj P; Rasool M
Medicine (Baltimore); 2022 Jul; 101(26):e29660. PubMed ID: 35777011
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
Eskazan AE; Ozmen D
Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
[No Abstract] [Full Text] [Related]
16. [Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy].
Tauchi T
Rinsho Ketsueki; 2018; 59(10):2089-2093. PubMed ID: 30305513
[TBL] [Abstract][Full Text] [Related]
17. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
Mahon FX
Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
[No Abstract] [Full Text] [Related]
18. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
Haematologica; 2017 Dec; 102(12):e486-e489. PubMed ID: 28860340
[No Abstract] [Full Text] [Related]
19. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
